These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 16026803

  • 1. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
    Oger J, Francis G, Chang P, PRISMS Study Group.
    J Neurol Sci; 2005 Oct 15; 237(1-2):45-52. PubMed ID: 16026803
    [Abstract] [Full Text] [Related]

  • 2. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 3. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA, Rivera VM.
    Curr Med Res Opin; 2010 Apr 26; 26(4):827-38. PubMed ID: 20121658
    [Abstract] [Full Text] [Related]

  • 4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 26; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 5. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul 26; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 6. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
    Mult Scler; 2009 Aug 26; 15(8):965-76. PubMed ID: 19465443
    [Abstract] [Full Text] [Related]

  • 7. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.
    J Neurol Sci; 2004 Jul 15; 222(1-2):13-9. PubMed ID: 15240190
    [Abstract] [Full Text] [Related]

  • 8. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 15; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 9. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
    Ann Neurol; 1996 Mar 15; 39(3):285-94. PubMed ID: 8602746
    [Abstract] [Full Text] [Related]

  • 10. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
    Cocco E, Marchi P, Floris G, Mascia MG, Deriu M, Sirca A, Mamusa E, Lai M, Mura M, Mallarini G, Marrosu MG.
    Funct Neurol; 2006 Mar 15; 21(3):145-9. PubMed ID: 17049133
    [Abstract] [Full Text] [Related]

  • 11. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 15; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 12. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M.
    Mult Scler; 2007 May 15; 13(4):490-501. PubMed ID: 17463072
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C.
    J Neurol Sci; 2012 Jan 15; 312(1-2):97-101. PubMed ID: 21880336
    [Abstract] [Full Text] [Related]

  • 14. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
    Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
    [Abstract] [Full Text] [Related]

  • 15. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT.
    Neurology; 2008 Oct 28; 71(18):1390-5. PubMed ID: 18525027
    [Abstract] [Full Text] [Related]

  • 16. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
    Mult Scler; 2010 Jan 28; 16(1):68-77. PubMed ID: 19995846
    [Abstract] [Full Text] [Related]

  • 17. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
    Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
    Mult Scler; 2010 Apr 28; 16(4):450-4. PubMed ID: 20150398
    [Abstract] [Full Text] [Related]

  • 18. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar 28; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 19. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
    Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
    Arch Neurol; 2008 Feb 10; 65(2):199-204. PubMed ID: 18071030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.